EV/EBITDA - Newron Pharmaceuticals SpA (SIX:NWRN) - Alpha Spread

Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.66 CHF -3.04%
Market Cap: 145.9m CHF
Have any thoughts about
Newron Pharmaceuticals SpA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-13.9
Current
-7.9
Median
13.9
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-13.9
=
Enterprise Value
149.3m CHF
/
EBITDA
-11.4m EUR
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
28
2-Years Forward
EV/EBITDA
79.4
3-Years Forward
EV/EBITDA
44

See Also

Discover More